RapidAI’s Rapid RV/LV Cleared by FDA as Part of Its PE Care Solution

February 22, 2023—RapidAI, a company focused on artificial intelligence (AI)–enhanced clinical decision support and patient workflow products for neurovascular and vascular treatment, announced it has received FDA 510(k) clearance for a new tool that allows physicians to quickly assess the ratio between the right ventricle (RV) and the left ventricle (LV) to determine severity of pulmonary embolism (PE), known as Rapid RV/LV. Automating this process will enable care teams to prioritize patients more quickly and to accelerate decision-making.

Rapid RV/LV is an addition to the company’s Rapid PE solution.

According to the company, Rapid RV/LV uses AI to analyze computerized tomography pulmonary angiograms (CTPAs) and automatically calculate the RV/LV ratio within minutes of the scan for quick conduct risk stratification for patients with right heart strain.

As a component of the Rapid PE solution, key benefits of Rapid RV/LV include quick identification of patients with possible right heart strain; reduction of time to diagnosis; and reduction of variability and standardization of RV/LV measurement.

Combined with the results from the Rapid PE triage and notification product, which notifies clinicians of suspected PE, and the workflow and communication tools of the Rapid Workflow mobile and web apps, Rapid RV/LV provides PE care teams with the information needed to make faster care decisions and to communicate with and activate the team for coordinated care, stated the company.

“Elevated risk PE is a treatable disease, but it is underdiagnosed. Rapid RV/LV will be key in identifying PE patients with right heart strain,” commented Peter Monteleone, MD, in RapidAI’s press release.

Dr. Monteleone, an interventional cardiologist at Ascension Texas Cardiovascular in Austin, Texas, continued, “The ability to access the RV/LV ratio along with CTPA images will allow clinicians to quickly identify patients who would benefit from further treatment, improving patient outcomes and saving lives. This will have a profound impact on our PE program here at Ascension.”